Arca
Skip to content
Tools
Tools

Kidney transplantation

Drug research and approvals for kidney transplantation: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 254 studies of kidney transplantation are recruiting on ClinicalTrials.gov, Health Canada has authorized 23 drug trials for it since 2013, and FDA has 0 approved and 2 open orphan designations naming it.

  • Recruiting worldwide: 254
  • Trials authorized in Canada: 23
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 254 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 6

Phase 1 or earlier 1

  • IscalimabTumor necrosis factor receptor superfamily member 5 inhibitor

Trials authorized in Canada

The 10 newest of 23; search them all in Canada trials
Aug 27, 2026A multicenter, phase 3 randomized, active-controlled, open-label study to evaluate the efficacy and safety of tegoprubart compared with tacrolimus in adult…Tegoprubart (AT-1501)Eledon PharmaceuticalsPending
Aug 24, 2026An adaptive, randomised controlled trial to treat polyomavirus infections (BKPYV) in kidney and kidney-pancreas transplant recipientsGamunex / IgivnexUniversity of QueenslandPending
Feb 25, 2026Advancing transplantation outcomes in childrenNulojix / RapamuneNational Institute of Allergy and Infectious Diseases (Niaid)Ongoing
Jan 6, 2026Renal ex vivo SYN002 perfusion to eliminate cmv transmission: a pilot safety trial in kidney transplant recipients. (short title: respect-cmv trial)SYN002University Health Network Ajmera Transplant CentrePending
Nov 26, 2025A seamless phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant and safety of…Frexalimab (SAR441344)Sanofi-Aventis Canada IncOngoing
Oct 30, 2025A double-blind, placebo-controlled, multicenter, randomized phase 2 trial evaluating the efficacy and safety of felzartamab in recipients of kidney transplants…FelzartamabBiogenOngoing
Jun 19, 2025A phase 2b, non-randomized, controlled, open-label, extension study to evaluate the persistence of immune response of the adjuvanted rsvpref3 vaccine and the…Bio RSV oa=adj (GSK3844766A)GSKOngoing
Apr 16, 2025Semaglutide for the prevention of post-transplant diabetes mellitus in kidney transplant recipientsRybelsus (semaglutide)University Health NetworkOngoing
Feb 11, 2025A phase 3, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of ravulizumab administered intravenously in…Ultomiris [ravulizumab (ALXN1210)]AstraZeneca PharmaceuticalsOngoing
Jun 12, 2024Evaluation of thiosulfate in end stage renal disease and kidney transplantationSodium thiosulfateLondon Health Sciences CentreOngoing

FDA orphan designations

Approved first, then open designations, newest first
May 31, 2023N-myristoylated -Glu-Ala-Val-Ser-Leu-Lys-Pro-ThrPrevention of ischemia/reperfusion injury in kidney transplantationYoung Therapeutics, LLCDesignated
Nov 30, 2016C1 esterase inhibitor (Human)Treatment of acute antibody mediated rejection following kidney transplantationTakeda Development Center Americas, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.